ORIC-114

DRUG3 trials

Sponsors

ORIC Pharmaceuticals Inc., ORIC Pharmaceuticals

Conditions

Food Effect in Healthy ParticipantsSolid Tumors

Phase 1

Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration

RecruitingNCT05315700

ORIC PharmaceuticalsSolid Tumors

Start: 2022-03-10End: 2027-09-01Target: 350Updated: 2026-09-04

Effect of Food on the Pharmacokinetics of ORIC-114

CompletedNCT06012721

ORIC PharmaceuticalsFood Effect in Healthy Participants

Start: 2023-09-11End: 2023-11-23Updated: 2024-01-19

An Open-Label, Phase 1/2 Study of ORIC-114 as a Single Agent or in Combination with Chemotherapy, in Patients with Advanced Solid Tumors Harboring an EGFR or HER2 Alteration

RecruitingCTIS2024-512264-66-00

ORIC Pharmaceuticals Inc.Solid Tumors

Start: 2025-01-29Target: 30Updated: 2025-05-18

Related Papers

First-Line Mobocertinib Versus Platinum-Based Chemotherapy in Patients With <i>EGFR</i> Exon 20 Insertion–Positive Metastatic Non–Small Cell Lung Cancer in the Phase III EXCLAIM-2 Trial

Journal of Clinical Oncology2025-01-2916 citations